Early access program for Molecular Dynamics' microarray technology gaining momentum.
This article was originally published in The Gray Sheet
Executive SummaryMOLECULAR DYNAMICS DEVELOPING TOXARRAY PRE-ARRAYED DNA TOXICOLOGY SLIDES in collaboration with Phase-I Molecular Technology, company President and CEO Jay Flatley reported at a Jan. 12 session of the Hambrecht & Quist health care conference in San Francisco. "With Phase-I, we will jointly be developing a series of pre-arrayed DNA slides called ToxArray, using their toxicology technology and then supplying that out to the pharmaceutical partners in our technology access group," Flatley said.
You may also be interested in...
The physician who led the first first-in-human robotic-assisted neurovascular intervention with Corindus’ CorPath GRX system believes the technology could revolutionize neurovascular intervention by allowing a centralized interventional team to remotely treat patients.
The disruptive medtech M&A of recent years was not matched in the past year for volume, but there were isolated outbreaks of major activity, as shown in our company rankings.
Hikma and Civica Rx have announced the launch of a first wave of eight essential injectable medicines, including heparin, as part of a deal struck between the two firms earlier this year.